The Exchange has sought clarification from Aarti Drugs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013 or as per Indian Accounting Standard The response of the Company is awaited.
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Aarti Drugs Limited to clarify why its financial results for the quarter ended 31 March 2025 do not follow the format prescribed by SEBI under Regulation 33 of the LODR Regulations, 2015. Two specific issues were flagged: the results are not in SEBI's prescribed format, and they also don't align with Schedule III of the Companies Act, 2013, or Indian Accounting Standards (Ind AS). The company has not yet responded to the exchange, and its reply is awaited.
This is a procedural compliance issue rather than a financial or governance concern. Investors should monitor the company's response, but the stock is unlikely to be materially impacted unless the clarification reveals deeper reporting problems.